Rethinking cancer clinical trials for COVID-19 and beyond.
Gary J DohertyMehmet GoksuBruno Henrique Rala de PaulaPublished in: Nature cancer (2020)
The risks posed to patients with cancer by the current COVID-19 pandemic demand rapid structural changes in healthcare delivery, with many positive changes likely to continue long term. An immediate critical reassessment of trial methodology based on clinical and scientific priorities is essential to ensure the resilience of clinical cancer research and optimize patient-centered care.